论文部分内容阅读
目的 :分析并探讨多索茶碱与氨茶碱治疗支气管哮喘的临床效果差异以及对肺功能改善的效果。方法:选取2014年1月~2016年1月在医院接受治疗的支气管哮喘患者160例,随机分为观察组(n=80)与对照组(n=80)。观察组给予多索茶碱治疗,对照组给予氨茶碱治疗,观察两组临床效果,第1秒用力呼气量(FEV1)、用力肺活量(FVC)、肺活量(VC)及不良反应。结果 :观察组有效率为91.25%,对照组有效率为80.00%。观察组有效率明显高于对照组。治疗后,观察组FEV1为(1.45±0.31)L,FVC为(2.16±0.35)L,VC为(2.91±0.50)L。对照组FEV1为(1.24±0.29)L,FVC为(1.92±0.37)L,VC为(2.53±0.51)L。两组肺功均有明显改善,观察组改善更加明显。观察组恶心4例,呕吐2例,失眠2例,发生率为10.00%。对照组恶心9例,呕吐6例,失眠3例,发生率为22.50%。观察组不良反应发生率明显低于对照组。结论 :与氨茶碱相比,多索茶碱治疗支气管哮喘临床效果更加显著,肺功能改善明显,且不良反应发生率低,临床上值得推广。
OBJECTIVE: To analyze and discuss the difference between the clinical efficacy of doxofylline and aminophylline in the treatment of bronchial asthma and its effect on the improvement of pulmonary function. Methods: One hundred and sixty patients with bronchial asthma who were treated in the hospital from January 2014 to January 2016 were randomly divided into observation group (n = 80) and control group (n = 80). The observation group was given doxofylline. The control group was treated with aminophylline. The clinical effects, FEV1, FVC, VC and adverse reactions were observed. Results: The effective rate was 91.25% in the observation group and 80.00% in the control group. Observation group, the effective rate was significantly higher than the control group. After treatment, the FEV1 in the observation group was (1.45 ± 0.31) L, the FVC was (2.16 ± 0.35) L and the VC was (2.91 ± 0.50) L. The FEV1 in the control group was (1.24 ± 0.29) L, the FVC was (1.92 ± 0.37) L and the VC was (2.53 ± 0.51) L. Two groups of lung function were significantly improved, the observation group improved more clearly. Observation group nausea in 4 cases, vomiting in 2 cases, insomnia in 2 cases, the incidence was 10.00%. In the control group, nausea occurred in 9 cases, vomiting in 6 cases and insomnia in 3 cases, with a rate of 22.50%. The incidence of adverse reactions in the observation group was significantly lower than that in the control group. Conclusion: Compared with aminophylline, Doxofylline is more effective in the treatment of bronchial asthma, with obvious improvement of pulmonary function and low incidence of adverse reactions, which is worth to be popularized clinically.